Ori-CAR-017

N/A

Report date: 2025/06/19 16:46:59

Base Information

Drug NameOri-CAR-017
Drug Alias NameOri-CAR-017GPRC5D-CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-GPRC5D
TargetsG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesOriCell Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsImmunoproliferative DisordersLymphoproliferative DisordersHemorrhagic Disorders +[9] 
Inactive IndicationsImmune System DiseasesCardiovascular DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A